|
India News Releases
|
(India.CityRegions.Com, May 14, 2016 ) The report provides comprehensive information on the therapeutics under development for MedImmune, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for MedImmune LLC and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of MedImmune, LLC - The report reviews pipeline therapeutics for MedImmune, LLC by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved MedImmune, LLC therapeutics and enlists all their major and minor projects - The report assesses MedImmune, LLC therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001236091/buying
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for MedImmune, LLC - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding MedImmune, LLC pipeline depth and focus of Indication therapeutics
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001236091/sample
Table of Content: An Overview
MedImmune, LLC Snapshot 6 MedImmune, LLC Overview 6 Key Information 6 Key Facts 6 MedImmune, LLC - Research and Development Overview 7 Key Therapeutic Areas 7 MedImmune, LLC - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licensed Products 19 MedImmune, LLC - Pipeline Products Glance 21 MedImmune, LLC - Late Stage Pipeline Products 21 MedImmune, LLC - Clinical Stage Pipeline Products 23 MedImmune, LLC - Early Stage Pipeline Products 27 MedImmune, LLC - Drug Profiles 30 MEDI-550 30
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001236091/discount
anifrolumab 32 benralizumab 34 durvalumab 37 durvalumab + tremelimumab 41 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine 43 moxetumomab pasudotox 44 tralokinumab 46 inebilizumab 48 dusigitumab 51 INO-3112 53 mavrilimumab 55 MEDI-2070 57 MEDI-3902 58 MEDI-4893 59 MEDI-6012 61 MEDI-7510 63 MEDI-8852 65 MEDI-8897 66 tremelimumab 67 inebilizumab + MEDI-0680 70 MEDI-0382 71 AMG-211 72 AMP-110 74 AMP-224 76 durvalumab + gefitinib 78 durvalumab + MEDI-0680 79 durvalumab + MEDI-6383 80 inebilizumab + rituximab 81
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001236091/buy/1500
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|